Nanobac Pharmaceuticals Intends to Join High Risk Plaque Initiative
Study May Provide Conclusive Data on the Role of Calcified
NanoParticles in Heart Disease
Last Update: 10:08 AM ET Aug 23, 2007
TAMPA, Fla., Aug 23, 2007 (BUSINESS WIRE) -- Nanobac Pharmaceuticals
Inc. (NNBP:
nanobac pharmaceuticals inc com NNBP 0.06, +0.00, +5.0%) , "Nanobac"
or "the Company" announces that it intends to participate in the High
Risk Plaque (HRP) Initiative to research and advance the
understanding, recognition and management of vulnerable plaque, the
primary underlying cause of heart attacks. The HRP Initiative is being
conducted by BG-Medicine (BGM) together with Merck & Co., AstraZeneca,
Royal Philips Electronics and Humana.
HRP's BioImage study enables Nanobac to validate and qualify the role
of Calcifying Nanoparticles (CNPs) also known as nanobacteria in
identifying the hard "calcified" portion of the atherosclerotic
plaque. Participation would allow Nanobac to study and document the
relationship between CNPs, advanced imaging studies, other blood
biomarkers and 3-year event rates. The information from the HRP
studies related to CNPs is expected to play an important role in any
regulatory submission for CNPs for cardiovascular disease.
CNPs were discovered by Company scientists and are found to be
associated with pathological calcifications. CNPs have been isolated
and cultured from atherosclerotic plaque, blood, and diseased
calcified tissues. They are infectious and their biomineralizing
properties well established with identified unique properties. They
can cause acute and chronic inflammation and lead to thrombosis. CNPs
have created a new paradigm similar to that of Prions. Prions, which
cause Mad Cow Disease, are now accepted by the scientific community as
infectious agents. Nanobac believes that CNPs form the nucleus of
pathological calcification in many diseases. The number one
pathological calcification disease is atherosclerosis.
Under the HRP Participant Agreement Nanobac is granted certain rights
in exchange for a total of $5M in funding by Nanobac over three years.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For
more information, visit our website at: nanobac.com.
SOURCE: Nanobac Pharmaceuticals Inc.
Nanobac Pharmaceuticals, Tampa Brady Millican, 813-264-2241 or
Redwood Consultants Jens Dalsgaard, 415-884-0348
Copyright Business Wire 2007 |
